 (Heart 1996;75:596-601) 
Setting-Tertiary cardiac referral centre. Main outcome measures-Clinical evaluation, echocardiography, and Holter monitoring at baseline, 6 months, and 1 and 2 years. Radionuclide ventriculography at rest and during exercise after 2 years. Endomyocardial biopsy at baseline and after a year if the initial diagnosis was myocarditis.
Results-Left ventricular ejection fraction was improved in 21 (81%) of 26 patients after interferon-a or thymomodulin administration and in 8 (66%) of 12 conventionally treated patients (P < 0.05) at 2 year follow up. The maximum exercise time was significantly longer at 2-year follow up in patients treated with immunomodulators (mean (SEM) 5.1 (0.6) minutes for interferon-a and 5*0 (0.4) minutes for thymomodulin) than in conventionally treated patients (3.3 (0.4) minutes). Left ventricular ejection fraction during exercise (assessed by radionuclide ventriculography) improved in 9 of 12 patients treated with interferon-a, 10 of 12 patients treated with thymomodulin, and 3 of 9 conventionally treated patients at 2 year follow up. The electrocardiogram was normal in 21 (88%) of 24 patients after interferon-a or thymomodulin treatment and 2 (22%) of 9 conventionally treated patients. At enumeration.'7-'9 Immunological studies were repeated weekly and monthly during the first six months of follow up.
The study design was a prospective, randomised, open label comparison of conventional treatment with conventional treatment plus immunomodulation with interferon-a or thymic hormones. After approval by the Institution Review Board and after consent forms were signed, the patients were randomly assigned to three treatment groups: (1) 12 patients received conventional treatment for congestive heart failure, (2) 13 patients received conventional treatment plus interferon-a; and (3) 13 patients received conventional treatment plus thymic hormone.
Treatment lasted for three months. For the next three months all patients received conventional treatment alone. The criteria for administration of conventional treatment were set at the beginning of the study. A specific stepwise conventional regimen, with identical doses in all treatment groups, was given by the same physician in the order listed below: * reduced salt intake (less than 4 g a day). * Digoxin (serum concentration of 1-2 mg/ml). * Frusemide (40-160 mg/day). * Captopril (25 mg three times a day). * Metolazone (2-5-5 mg/day). * Warfarin (if LVEF was < 35%) to maintain the international normalised ratio for prothrombin time in the range 2 5-4 0. These steps were followed in order as necessary.
Purified leucocytic interferon-a (Torlak, Beograd) was given at 3 million U/M2 of body surface area subcutaneously three times a week. Thymus-TFX Thymomodulin (10 mg) (Thymoorgan, Pharmazie, Vieneburg, Germany) was given subcutaneously three times a week. Thymus-TFX thymomodulin is a biologically active extract of the thymus gland of calves consisting of polypeptides between 4000 and 6000 daltons.
At six month, one year, and two year follow up we performed clinical evaluation, echocardiographic studies (biplane method for LVEF measurements), chest x rays, and Holter monitoring. At one year, we repeated the right ventricular endomyocardial biopsy if the initial diagnosis was myocarditis. At two years radionuclide ventriculography gated bloodpool technique was performed at rest and during exercise.
STATISTICAL ANALYSIS
Measurements were mean (SEM). Statistical analysis was performed using analysis of variance for repeated measures (Newman-Keuls multiple comparisons) and analysis of variance by the modified t test (Bonferroni) as appropriate. Results were regarded as significant if P was less than 0 05.
Results
Four patients had histological diagnosis of active and 11 patients of borderline myocarditis. Their average age at presentation was 29-3 years (range 19-40 years). Twenty three patients had a histological diagnosis of idiopathic dilated cardiomyopathy (mean age at presentation of 31-7 years (range years)).
We found raised virus neutralising antibody titres, usually to Coxsackie B viruses, in 14 patients.
At the start of the study two patients were in New York Heart Association class II, 26 patients were in class III, and 10 in class IV. There was no significant baseline medical difference among the three treatment groups.
Left ventricular function assessed by angiography at the beginning of the study was similar (LVEF was 22-7 (1-2)% in patients treated with interferon-a, 22 (14) % in patients treated with thymomodulin, and 23-9 (1.1)% in con- (fig 4) . In seven conventionally treated patients, the ejection fraction decreased or failed to increase on exercise, indicating an abnormal haemodynamic response. Maximum exercise time at two year follow up was 5-1 (0 6) minutes in the interferon-a group, 5 (0 4) minutes in thymomodulin group, and 3-3 (0-4) minutes in the conventionally treated group (P < 0-01, analysis of variance, modified t test, Bonferroni).
Biopsy was repeated at one year. In five patients with initial diagnosis of myocarditis who were treated with interferon-a (two active and three borderline) myocarditis had resolved. Of five patients treated with thymomodulin (one active and four borderline myocarditis), one had resolving myocarditis and four had resolved myocarditis. In the conventionally treated group, one patient who initially had active myocarditis had resolving myocarditis, two who initially had borderline myocarditis had resolved myocarditis, and two who initially had borderline myocarditis had a histological diagnosis of dilated cardiomyopathy. igure 5 NYHA classification at two year follow up in 38 patients with dilated heart muscle disease.
In nine patients treated with interferon-a and six treated with thymomodulin NYHA class had improved at one year ( fig 5) . At two year follow these patients maintained their improvement. In five conventionally treated patients the functional class had improved at one year, and in one of them it had worsened again at two year follow up.
One interferon-a treated patient with biopsy confirmed idiopathic dilated cardiomyopathy died five months after presentation. It was a sudden death outside hospital. One thymomodulin treated patient died at nine months of an embolic cerebrovascular accident. Three patients in the conventionally treated group died during two year follow up-one suddenly and two from end stage cardiac failure. Discussion Dilated heart muscle disease can be idiopathic (IDC) Four of the 13 patients treated with thymomodulin had a slight, but transient increase in weight. In two women menstrual bleeding was prolonged.
Patients with a left ventricular ejection fraction < 30% have a poor prognosis and many such patients are on a progressively downhill course and are likely to die within a few years. The poor prognosis of idiopathic heart muscle disease justifies the continued pursuit of new treatments. We believe that the improvement in cardiac function that occurred during the two year follow up in patients with idiopathic myocarditis or idiopathic dilated cardiomyopathy treated with interferon-a or thymomodulin may have been the result of enhancement of immune function in patients who had a chronic myocardial viral infection.
Our results suggest that a combination of interferon-a and thymomodulin could improve function more than either drug given on its own-because of the early effects of interferon and the sustained effects of thymomodulin on immune function.
